About
Praveen Tipirneni, MD, is a biotech executive and venture operator based in Boston. Atlas Venture lists him as a Venture Partner and Chief Executive Officer of Caldera Therapeutics, and BridgeBio Oncology Therapeutics lists him as a Non-Executive Director. He previously led Morphic Therapeutic from its founding until its acquisition by Eli Lilly for $3.2 billion and has also served on the board of Tectonic Therapeutic.
Areas of interest
biotechdrug developmenttherapeuticshealthcare strategyventure investinglife sciences